Bio-Rad Laboratories (BIO) Shareholder's Equity Growth (5y) (2014 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Bio-Rad Laboratories | 8.23 Bn | 6.66 Bn | 309.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.37% |
| Dec 31, 2025 | -5.50% |
| Sep 30, 2025 | -5.26% |
| Jun 30, 2025 | -0.62% |
| Mar 31, 2025 | 1.20% |
| Dec 31, 2024 | 2.68% |
| Sep 30, 2024 | 7.85% |
| Jun 30, 2024 | 4.32% |
| Mar 31, 2024 | 13.23% |
| Dec 31, 2023 | 16.81% |
| Sep 30, 2023 | 11.42% |
| Jun 30, 2023 | 12.73% |
| Mar 31, 2023 | 16.82% |
| Dec 31, 2022 | 26.83% |
| Sep 30, 2022 | 24.37% |
| Jun 30, 2022 | 26.05% |
| Mar 31, 2022 | 30.39% |
| Dec 31, 2021 | 39.62% |
| Sep 30, 2021 | 41.50% |
| Jun 30, 2021 | 34.70% |
| Mar 31, 2021 | 33.05% |
| Dec 31, 2020 | 31.82% |
| Sep 30, 2020 | 29.43% |
| Jun 30, 2020 | 25.53% |
| Mar 31, 2020 | 23.41% |
| Dec 31, 2019 | 21.40% |
| Sep 30, 2019 | 18.71% |
| Jun 30, 2019 | 19.52% |
| Mar 31, 2019 | 16.85% |
| Dec 31, 2018 | 12.95% |
| Sep 30, 2018 | 18.20% |
| Jun 30, 2018 | 17.50% |
| Mar 31, 2018 | 17.18% |
| Dec 31, 2017 | 69.05% |
| Sep 30, 2017 | 8.03% |
| Jun 30, 2017 | 8.70% |
| Mar 31, 2017 | 8.04% |
| Dec 31, 2016 | 1,437.70% |
| Sep 30, 2016 | 9.80% |
| Jun 30, 2016 | 8.66% |
| Mar 31, 2016 | 9.55% |
| Dec 31, 2015 | 10.04% |
| Sep 30, 2015 | 11.21% |
| Jun 30, 2015 | 12.61% |
| Dec 31, 2014 | 11.29% |